Business Wire

MORINAGA-MILK-INDUSTRY

Share
Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-63 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and children foods (under the age of three) on 25 July, 2024. This approval marks a significant milestone for the company, making it the only Japanese firm to have three bifidobacteria strains registered for use in China’s infant and toddler food market1.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808893280/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)

*1 Source: Public announcement published on the website of the China National Center for Food Safety Risk Assessment (August 5, 2024)

The newly registered Bifidobacterium infantis M-63 joins Morinaga Milk’s other approved strains, Bifidobacterium breve M-16V and Bifidobacterium longum BB536. All three strains are now permitted for use in foods for children under three years old in China, meeting the country's stringent nutritional and safety standards.

Expanding Global Presence

This approval aligns with Morinaga Milk’s 10-year vision to become a globally recognized company with a significant international presence. As part of this vision, the company aims to achieve a Global Business sales ratio of 15% or more by the fiscal year ending in March 2029. The approval of Bifidobacterium infantis M-63 represents a strategic step towards this goal, allowing Morinaga Milk to strengthen its bacteria business in the Chinese market, which accounts for more than 40% of the global formula milk market and is the second-largest supplement market worldwide2.

*2 Source: Survey by Euromonitor International (May 2024), based on retail sales prices

Health Benefits of Bifidobacterium infantis M-63

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. With China's recent approval of HMO use in formula milk in October 20233, the combination of Bifidobacterium infantis M-63 and HMO is expected to support the growth of beneficial intestinal bacteria, enhancing the development and health of infants and toddlers4.

*3 Source: National Health Commission of the People’s Republic of China, No. 8, 2023 (Sept. 22, 2023)
*4 Source: Mintel, “HMOs approval in China infant formula is a game changer” (Jan. 2024)

Probiotics strain of bifidobacteria registered as New Food Ingredients in China

Strain

Registration date

Bifidobacterium breve M-16V

Registered name: 短双歧杆菌 M-16V

2016

Bifidobacterium longum subsp. longum BB536

Registered name: 长双歧杆菌长亚种 BB536

2022

Bifidobacterium longum subsp. infantis M-63

Registered name: 长双歧杆菌婴儿亚种M-63

2024

* All three strains are approved for use in foods for infants and toddlers under the age of three.

Commitment to Quality and Research

Morinaga Milk has been at the forefront of bifidobacteria research since discovering Bifidobacterium longum BB536 in 1969. The company leads globally in the number of clinical research papers on bifidobacteria, underlining its commitment to advancing scientific understanding and improving public health.

Future Prospects

The registration of Bifidobacterium infantis M-63 paves the way for its use in a wide range of products. Morinaga Milk plans to leverage this approval to expand collaborations with major formula milk manufacturers and promote supplements and other related products in China and globally. By providing accurate information on the benefits of Bifidobacterium infantis M-63 to consumers and partners, Morinaga Milk aims to enhance the health and nutrition of people worldwide.

About Morinaga Milk Industry

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808893280/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release

Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi

Kinaxis to Host Inaugural European User Conference Showcasing Supply Chain Innovators17.9.2025 13:00:00 CEST | Press release

Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced its inaugural customer conference in Europe. Kinexions EMEA 2025 will be held October 6 – 8 in Amsterdam NL, bringing together global supply chain leaders from ExxonMobil, Bosch, and more. Following the success of Kinexions conferences in North America and Asia, expanding Kinexions into Europe meets the needs of a growing customer community in the region and reflects the growing community of leaders in the region who are driving some of the most innovative and resilient supply chain transformations today. That momentum is reflected in Kinaxis’ 18% year-over-year revenue growth in Europe, underscoring rising demand for AI-driven orchestration on the Kinaxis Maestro® platform. Why It Matters As supply chains face ongoing pressure from the dynamic tariff environment, geopolitical risk, ESG regulation, and many other disruptions, companies are accelerating digital transformation efforts. Kin

Allied Telesis Launches SwitchBlade® x908 Generation 3 to Solve Enterprise and Data Center Scalability Challenges17.9.2025 11:40:00 CEST | Press release

Compact 3U modular chassis delivers capacity-on-demand flexibility and first Allied Telesis 400G support. Enterprises and data centers face mounting challenges in scaling their networks to support AI, video, IoT, and virtualized workloads. Bandwidth demand is rising, yet many organizations are held back by legacy switches, fragmented operations, and the high cost of oversized chassis systems. To address these issues, Allied Telesis today announced the SwitchBlade x908 Generation 3 (SBx908 GEN3), a next-generation modular switch that combines high-density performance, flexible interface modularity, and future-proof scalability in a compact 3U form factor. Customers can expand capacity on demand with a wide range of interface modules, tailoring the platform to their evolving requirements. Why SBx908 GEN3? The SBx908 GEN3 was developed in direct response to customer demand for scalable, space-efficient networking. Its capacity-on-demand model allows customers to start with only the ports

LTIMindtree Partners with Shopify to Launch an AI Commerce Center of Excellence17.9.2025 11:30:00 CEST | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced a partnership with Shopify, an AI powered commerce platform for enterprises that empowers businesses to launch, manage, and grow their online stores. Leveraging the Shopify platform, LTIMindtree will set up an AI enabled Center of Excellence (CoE) for Digital Commerce that will help global enterprises to transform at the speed of AI and innovate at scale. LTIMindtree Interactive, the AI-led agency unit of LTIMindtree, is driving the next wave of enterprise digital commerce transformation for CMOs across the globe. Shopify, trusted by millions of merchants, provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. Leveraging the Shopify platform, LTIMindtree will power an AI-driven Centre of Excellence to develop a best-in-class CoE that will: Build advanced AI commerce capabilities to help

Alpha’s latest report explores the impact of retail investors on fund finance provision17.9.2025 11:00:00 CEST | Press release

Alpha Group International plc (LON:ALPH) today announced the launch of its latest Lender Book Report, exploring and analysing the latest fund finance market trends. What does retail investment mean for subscription lines? Private capital funds, once the reserve of institutions such as pension funds and sovereign wealth funds, are rapidly opening up to a wider base of potential investors. Indeed, last month saw President Trump issue an executive order calling for expanded access to private equity and other alternative investments for 401(k) plans and their participants. While the push to open up private capital markets will undoubtedly see an influx of capital coming from new investor types, it also throws up a whole host of ramifications that need to be addressed. One of which is the impact on fund financing, namely subscription line loans. Traditionally, these facilities are secured against capital commitments from institutional investors into an alternative asset manager’s closed-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye